Xi'an Ximan Hongtu Information Technology Co., Ltd.

Founded in 2019, our journey has been one of strategic evolution: From a regional pharmaceutical intermediate trader to a globally recognized partner for integrated cross-border supply and technical solutions. With over six years of concentrated expertise in the pharmaceutical and fine chemical sectors, we are dedicated to the mission of "Empowering Pharmaceutical Innovation. " By proactively navigating industry shifts and capitalizing on emerging opportunities, we have established a reputation for reliability and built solid, enduring partnerships across the globe.

Our track record is a testament to our capabilities. We proudly maintain long-term, collaborative relationships with a diverse network of over 280 clients spanning more than 60 countries and regions, including key markets in Europe, North America, Asia-Pacific, and Latin America. Our products command a 7% share in the global high-value API intermediate market, a position fortified by a strong intellectual property portfolio of 15 technical patents and 8 successfully commercialized high-value products. Financially robust, we have delivered consistent growth with an average annual revenue increase of 12% over the past five years. Uncompromising on quality, we have kept our customer complaint rate below 0.5% for eight consecutive years. This commitment to "zero defect" is enforced through strict adherence to ISO 9001 and GMP certified management systems and has been recognized with honors such as "Outstanding Cross-Border Trade Enterprise. "

Our core expertise lies in the seamless integration of cross-border trade and deep technical services for a comprehensive range of pharmaceutical intermediates. This includes API intermediates, fine chemical intermediates, and custom-synthesized products. Beyond supply, we provide end-to-end technical support encompassing process optimization, green synthesis pathway consulting, biocatalysis technology transfer, and collaborative joint R&D programs. All our products and processes are designed to comply with the rigorous standards of major regulatory bodies like the FDA, EMA, and CFDA, serving critical therapeutic fields such as oncology, cardiovascular, anti-infective, and neurological disorders.

Guided by the principle of "Quality First, Service Excellence, and Continuous Improvement, " and driven by our quality objective of "Zero Defect, Zero Complaints, " our strategic vision is focused on three key growth vectors:

Market Expansion:  Deepening our presence in high-potential emerging markets across Southeast Asia, Africa, and the Middle East by cultivating strong local networks and tailoring our approach to regional regulatory landscapes.

Innovation Acceleration:  Elevating our R&D investment to 15% of annual revenue to pioneer advancements in biocatalysis and green chemistry, with a target of introducing 3-5 novel high-value products to the market each year.

Supply Chain Transformation:  Building a resilient, digital supply chain ecosystem through advanced ERP integration and partnerships with top-tier logistics providers, aiming to reduce operational lead times by 20% and guarantee timely, efficient global delivery.

Upholding the core values of "Integrity, Innovation, and Win-Win Collaboration, " we are committed to advancing our role as a leading global enabler in the pharmaceutical intermediate sector. Our goal is to drive industry progress towards greater sustainability and high-quality development. We welcome the opportunity to connect and explore how our professional, tailored solutions can meet your specific needs.